Biotech Values

[dewophile]

Any Thoughts on the link.

from the link, along with some of my comments:

Cyclophilin inhibitors such as Debio 025 provide a novel approach to treatment by targeting host proteins that are involved in the growth of the hepatitis C virus. (interesting approach that is distinct from what pretty much everyone else out there is targeting - namely one of viral proteins, particularly protease or polymerase. it would seem to me there is also apt to be less risk of resistance than agents targeting elements within the viral machinery that are prone to mutate) Results of a Phase II study show that Debio 025 significantly reduced HCV replication when used alone, and had an important additive anti-HCV effect (4.6 log10 reduction) in combination with pegylated interferon alfa-2a in treatment-naïve patients1. (potency seems average - about 2 log delta at 4 weeks - and certainly less than many of the direct acting antiviral agents) No significant safety issues have been identified so far. (i'd be particularly worried about safety in a drug that targeted a host protein - but seems ok so far..)